GENOSAFE SAS

Their core work

Genosafe is a French private company specializing in biosafety testing and quality control for gene therapy and cell therapy products. Based in Évry — a major French biotech hub — they provide critical analytical and testing services needed to bring advanced therapy medicinal products (ATMPs) into clinical trials. Their H2020 work focuses on supporting gene therapy programs for rare diseases, contributing specialized vector characterization and safety assessment expertise to multi-partner clinical research consortia.

What they specialise in

How they've shifted over time

Genosafe's early H2020 involvement (2018) centered on specific in vivo gene therapy clinical trials — AAV vector delivery for liver metabolic disease (Crigler-Najjar) and retinal gene therapy (Usher syndrome). By 2020, their participation broadened into the wider advanced therapies ecosystem through ARDAT, which encompasses both gene and cell therapy research infrastructure. This shift suggests a move from project-specific testing services toward becoming a platform-level resource for the entire advanced therapies field.

Genosafe is broadening from niche gene therapy testing into a comprehensive advanced therapies service provider, positioning them as a go-to partner for any EU consortium developing ATMPs.

How they like to work

Genosafe operates exclusively as a specialist participant — never coordinating, always contributing domain-specific testing expertise to larger consortia. With 52 unique partners across 16 countries from just 3 projects, they work in large, internationally diverse consortia typical of major EU clinical research initiatives. This pattern indicates a service-provider role: teams invite Genosafe for their specific biosafety and quality testing capabilities rather than Genosafe driving research agendas.

Despite only 3 projects, Genosafe has built a remarkably broad network of 52 partners across 16 countries, reflecting the large consortium sizes of clinical gene therapy trials. Their network spans most of Western and Southern Europe's gene therapy research community.

What sets them apart

Genosafe occupies a critical niche at the intersection of gene therapy innovation and regulatory compliance — they are the testing and quality assurance layer that clinical programs need to advance from lab to patient. As a specialized SME in France's Genopole biotech cluster (Évry), they offer the kind of focused biosafety expertise that academic-led consortia typically lack in-house. For consortium builders planning gene or cell therapy clinical trials, Genosafe solves the specific problem of GMP-compliant vector and product testing.

Highlights from their portfolio

• UshTher
  Largest funding allocation (EUR 527,952) and technically ambitious dual-AAV approach to treat inherited blindness in Usher syndrome patients.
• ARDAT
  Most recent and longest-running project (2020-2026), representing Genosafe's expansion into the broader advanced therapies ecosystem beyond single-disease trials.
• CureCN
  First-in-human AAV gene therapy trial for Crigler-Najjar syndrome, a milestone project for liver-directed gene therapy with vector readministration research.